Type of malignancy and treatments in the oncological cohort
| Oncology patients N=176 | |
|---|---|
| Total haematological tumours n (%) | 35 (19.9) |
| Leukaemia* | 20 (10.9) |
| Lymphoma | 13 (7.1) |
| Multiple myeloma | 2 (1.1) |
| Underwent BMT† | 8 (22.8)† |
| Total solid tumours n (%) | 141 (80.1) |
| Lung cancer | 32 (17.5) |
| Breast cancer | 20 (10.9) |
| Pancreatic cancer | 14 (7.7) |
| Bladder cancer | 13 (7.1) |
| Prostate cancer | 12 (6.6) |
| Ovarian cancer | 8 (4.4) |
| Colon cancer | 8 (4.4) |
| Cholangiocarcinoma | 8 (4.4) |
| Liver cancer | 7 (3.8) |
| Rectal cancer | 6 (3.3) |
| Laryngeal cancer | 4 (2.2) |
| Other‡ | 16 (8.7) |
| Current chemotherapy regiment n (%) | 147 (83.5) |
| Current radiation therapy n (%) | 62 (35.2) |
*Includes acute and chronic leukaemia.
†Percentage is out of the total of haematological malignancy patients (ie, N=35).
‡Gastric, kidney, thyroid, brain, oesophageal, sarcoma, nasopharyngeal, thymus and anal cancer.
BMT, bone marrow transplantation.